Logo

Abbott's CardioMEMS HF System Receives the US FDA’s Approval for the Treatment of Heart Failure

Share this
Abbott's CardioMEMS HF System Receives the US FDA’s Approval for the Treatment of Heart Failure

Abbott's CardioMEMS HF System Receives the US FDA’s Approval for the Treatment of Heart Failure

Shots:

  • The US FDA has approved an expanded indication for CardioMEMS HF System to support the patients care living with HF & for patients who undergo a blood test showed elevated levels of biomarkers that indicate worsening HF
  • The approval was based on data on the (GUIDE-HF) trial in 3600 patients at 118 centers in North America which showed a 19% reduction in composite EPs of all-cause mortality & total heart failure events, 28% reduction in HF hospitalizations & improved care for patients with HF
  • The CardioMEMS HF System is a small implantable sensor & a paperclip-sized device that placed in the pulmonary artery during an MIS, monitors for pressure changes indicating worsening HF

 Ref: PR Newswire | Image: APK Pure

Click here to­ read the full press release 

Tuba

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions